Introduction
Medication use in children requires additional attention to the chemical processes induced by the active elements of drugs. Before the age of 16, young people’s bodies undergo significant growth and development as their systems mature. As a result, they may not respond to different medications in the same way as adults. In the case of some drugs, the differences between adults and children are substantial, and improper prescriptions can lead to long-term issues. Nevertheless, off-label use is often necessary for treatment; however, professionals should exercise caution to prevent potential side effects.
Off-Label Medications for Children
Clinicians cannot prescribe off-label without considering available options. Off-label use should not occur if drugs tested and approved for children exist – they should become first-line treatments. The dosage of these drugs has been established in trials, and their effects are documented. Furthermore, off-label use is not necessary for mild conditions, as the lack of available medication does not pose a threat to the child’s life and well-being.
However, for some children and adolescents, the absence of a tested solution presents a significant danger to their health. Here, professionals should use drugs typically administered to adults and apply evidence-based knowledge to determine the correct dosage. For instance, Panther et al. (2017) find that most medications for treating attention deficit/hyperactivity disorder (ADHD) do not have alternatives or official dosages for pediatric patients.
At the same time, children with ADHD may have trouble communicating and interacting with the school curriculum, which presents a significant risk for their development. These circumstances necessitate the clinician’s engagement in off-label use to treat the patient. Another situation could occur if the tested drugs are ineffective in a child – the clinician may try to use alternatives usually used for adults to see if they have a better effect. Thus, the main criterion for prescribing off-label is the unavailability of approved medications when the condition disrupts one’s life.
To make off-label use safer, healthcare providers must follow specific guidelines and rely on both scholarly and practical expertise. First, it is essential to consider the child’s age, as it determines how they interact with a drug. Children under one year are significantly different from adults, as their systems are still developing. For them, even small doses of unapproved medications may lead to significant consequences (Rosenthal & Burchum, 2021). Here, adjustments according to the child’s body weight are insufficient, as young children experience drug effects more intensely. Thus, the clinician should estimate absorption time and drug levels in the blood.
For children older than one year, the use of drugs becomes easier to predict, but precautions are still crucial. For example, the dosage may be calculated by multiplying the child’s body surface area by the adult dosage and then dividing this number by 1.73 m² (Rosenthal & Burchum, 2021). This calculation helps to estimate the needed amount better than one’s weight.
Next, providers must remember that some types of drugs are more dangerous than others. For instance, antidepressants, such as Zoloft, Wellbutrin, or Paxil, are believed to increase the risk of suicide in children (Rosenthal & Burchum, 2021). If the child’s depression is severe, as determined by official tests, one may consider using these medications (Poznanski & Mokros, 1996). Thus, one should evaluate whether using the drug has more benefits than its risks.
Conclusion
To conclude, pediatric off-label use is common due to the unavailability of information about some drugs. To engage in this practice, professionals must ensure that no other options are available. Moreover, they should weigh the child’s well-being against the potential side effects. The dosage should be calculated using the body surface area rather than weight to make off-label use safer. Furthermore, some drugs must be considered with increased scrutiny as they expose the child to severe dangers.
References
Panther, S. G., Knotts, A. M., Odom-Maryon, T., Daratha, K., Woo, T., & Klein, T. A. (2017). Off-label prescribing trends for ADHD medications in very young children. The Journal of Pediatric Pharmacology and Therapeutics, 22(6), 423-429.
Poznanski, E., & Mokros, H. (1996). Child Depression Rating Scale – Revised. Western Psychological Services.
Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.) Elsevier.